FDA OKs Drug for Rare Lipid Disorder

The FDA has approved the lipid-lowering drug lomitapide (Juxtapid) as add-on therapy in patients with a rare lipid disorder, the agency announced Wednesday.


The drug is for homozygous familial hypercholesterolemia (HoFH) patients and is designed to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol.


The drug should be paired with a low-fat diet and other lipid-lowering medications, the agency stated.


HoFH is a rare genetic condition that, if untreated, can cause extremely high cholesterol levels, typically between 400 mg/dL and 1,000 mg/dL. HoFH affects roughly one in 1 million people in the U.S.

Source: http://www.health.am/cholesterol/more/fda-oks-drug-for-rare-lipid-disorder/

Full Article Full Report Read Full Article Read Full Report